PAI Life Sciences Doses First Healthy Volunteer in Schistosomiasis Vaccine Clinical Trial
yahoo.com
news
2022-05-31 09:30:00

Deadly tropical disease threatens hundreds of millions worldwide

SEATTLE, May 31, 2022--(BUSINESS WIRE)--PAI Life Sciences, a biotechnology company specializing in translational research for neglected tropical diseases, today announced the dosing of the first healthy volunteer in a clinical trial of SchistoShieldÂ®, the company's preventive vaccine against schistosomiasis, a major tropical disease threatening nearly 1 billion people in 79 countries with more than 260 million people currently infected.
